Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
40000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status of the 18th Stock Acquisition Rights issued through a third-party allotment (with provisions for adjustment of the exercise price and suspension of exercise)
Who receives how much
Number of shares delivered during the month: 40,000 shares (40,000 new shares and 0 shares of treasury stock transferred)
EVO FUND (issued on 4 December 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
Existing Shares and Increase
+1.40%Rate of increase
3,230,228 shares3,270,228Shares
Exercise ratio subject to exercise restrictions: 1.4% (40,000 shares / 2,950,228 shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price during the subject month: ¥414–¥423. An exercise price adjustment clause applies. The floor for adjustments is Not disclosed.
Number of Stock Acquisition Rights
Total number issued: 10,000; number exercised during the subject month: 400; number unexercised at the end of the preceding month: 7,200; number unexercised at the end of the subject month: 6,800
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Timing 4 December 2025 / Type Issuance of the 18th Stock Acquisition Rights allocated to EVO FUND / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the 18th Stock Acquisition Rights issued through a third-party allotment (with provisions for adjustment of the exercise price and suspension of exercise) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 40,000 shares (40,000 new shares and 0 shares of treasury stock transferred) |
| Intended allottee | EVO FUND (issued on 4 December 2025) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 1.4% (40,000 shares / 2,950,228 shares) |
| Total number of issued shares | 3,230,228 shares (as of the end of the month preceding the subject month) → 3,270,228 shares (calculated figure as of the end of the subject month) |
| Exercise price | Exercise price during the subject month: ¥414–¥423. An exercise price adjustment clause applies. The floor for adjustments is Not disclosed. |
| Number of Stock Acquisition Rights | Total number issued: 10,000; number exercised during the subject month: 400; number unexercised at the end of the preceding month: 7,200; number unexercised at the end of the subject month: 6,800 |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Timing 4 December 2025 / Type Issuance of the 18th Stock Acquisition Rights allocated to EVO FUND / Amount Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the stock acquisition rights.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.